Ultragenyx Pharmaceutical (NASDAQ:RARE) – Analysts at Leerink Swann upped their Q1 2018 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a research report issued to clients and investors on Tuesday, April 17th. Leerink Swann analyst J. Schwartz now expects that the biopharmaceutical company will post earnings per share of ($1.91) for the quarter, up from their previous forecast of ($2.12). Leerink Swann also issued estimates for Ultragenyx Pharmaceutical’s Q2 2018 earnings at ($1.94) EPS, Q3 2018 earnings at ($1.97) EPS, Q4 2018 earnings at ($1.98) EPS, FY2018 earnings at ($7.80) EPS, FY2019 earnings at ($6.81) EPS, FY2020 earnings at ($4.64) EPS and FY2021 earnings at ($2.59) EPS.

RARE has been the subject of several other reports. BidaskClub lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Morgan Stanley restated an “equal weight” rating and set a $60.00 price target (up from $57.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 21st. Credit Suisse Group assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 17th. They set an “outperform” rating and a $67.00 price target for the company. Finally, JMP Securities upped their price target on shares of Ultragenyx Pharmaceutical from $70.00 to $74.00 and gave the company an “outperform” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $69.76.

NASDAQ RARE opened at $54.26 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $41.67 and a 12-month high of $71.99. The stock has a market cap of $2,723.86, a price-to-earnings ratio of -7.23 and a beta of 1.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.00) by ($0.27). The business had revenue of $2.41 million for the quarter, compared to analyst estimates of $0.75 million. During the same period last year, the firm posted ($1.75) EPS.

Several institutional investors have recently bought and sold shares of the company. California Public Employees Retirement System boosted its holdings in shares of Ultragenyx Pharmaceutical by 3.1% during the third quarter. California Public Employees Retirement System now owns 40,300 shares of the biopharmaceutical company’s stock worth $2,146,000 after purchasing an additional 1,200 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 6.5% during the fourth quarter. UBS Asset Management Americas Inc. now owns 26,662 shares of the biopharmaceutical company’s stock worth $1,237,000 after purchasing an additional 1,636 shares during the period. Jane Street Group LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 26.1% during the fourth quarter. Jane Street Group LLC now owns 8,821 shares of the biopharmaceutical company’s stock worth $409,000 after purchasing an additional 1,828 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its holdings in shares of Ultragenyx Pharmaceutical by 11.7% during the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 19,098 shares of the biopharmaceutical company’s stock worth $885,000 after purchasing an additional 2,000 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 4.0% during the fourth quarter. Swiss National Bank now owns 69,952 shares of the biopharmaceutical company’s stock worth $3,244,000 after purchasing an additional 2,700 shares during the period. Institutional investors own 87.19% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Q1 2018 Earnings Forecast for Ultragenyx Pharmaceutical (RARE) Issued By Leerink Swann” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/04/20/q1-2018-earnings-forecast-for-ultragenyx-pharmaceutical-rare-issued-by-leerink-swann.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.